Your session is about to expire
← Back to Search
Cabozantinib + Nivolumab +/- Ipilimumab for Genitourinary Cancers
Study Summary
This trial is studying the side effects and best doses of cabozantinib s-malate and nivolumab with or without ipilimumab to treat patients with genitourinary tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have certain reproductive, infectious, or autoimmune conditions.I have not had certain cancer treatments recently.I do not have active brain tumors, serious heart, stomach, or other major health issues.I have a confirmed metastatic genitourinary cancer with at least one measurable tumor or a new bone lesion.I have a confirmed diagnosis of a specific type of metastatic genitourinary cancer with new or worsening lesions.I am 18 years old or older.My cancer tissue is available for PD-L1 testing.I am able to care for myself but may not be able to do active work.My recent lab tests show my organs are functioning well.I had major surgery recently.
- Group 1: Part II (cabozantinib s-malate, nivolumab, ipilimumab)
- Group 2: Part I (cabozantinib s-malate, nivolumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the total capacity of participants in this clinical trial?
"This research is not currently enrolling patients. According to the data posted on 7/9/2015 and updated 10/1/2022, this trial has concluded participant recruitment. Although, there are 5,621 trials actively recruiting participants with metastatic sarcomatoid renal cell carcinoma and 840 studies for Ipilimumab seeking volunteers."
How many health-care settings are conducting this research?
"This clinical trial is currently enrolling patients at 8 different sites, such as the Ohio State University Comprehensive Cancer Center in Columbus, City of Hope Comprehensive Cancer Centre in Duarte and Los Angeles County-USC Medical Centre in LA. Additionally there are 5 further locations where participants may be recruited."
Has Ipilimumab earned clearance from the FDA?
"Due to the limited evidence of safety and efficacy, Ipilimumab was assigned a score of 1."
Has there been any other research conducted on Ipilimumab's efficacy?
"Presently, 94 Phase 3 studies for Ipilimumab are underway with a total of 840 trials being conducted globally. Of those, several are located near Pittsburgh in Pennsylvania and the remaining 46020 locations span across the entire world."
Are there still opportunities to join this clinical research initiative?
"This medical research is no longer recruiting individuals. It was first posted on July 9th 2015 and last amended October 1st 2022. Patients with metastatic sarcomatoid renal cell carcinoma should look into the 5621 clinical trials that are actively seeking participants, while those looking for Ipilimumab treatment can explore 840 studies currently enrolling patients."
What maladies has Ipilimumab been used to address?
"Ipilimumab may be used to combat the development of unresectable melanoma, squamous cell carcinoma, and to prevent a relapse in high-risk patients."
Share this study with friends
Copy Link
Messenger